The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

被引：0
|
作者：
Yu, Guopan [1 ]
Yao, Zurong [1 ]
Yin, Zhao [1 ]
Zhang, Yu [1 ]
Zhao, Weihua [2 ]
Weng, Guangyang [3 ]
Guo, Ziwen [4 ]
Sun, Zhiqiang [5 ]
Shi, Pengcheng [1 ]
Jiang, Xuejie [6 ]
Xu, Dan [1 ]
Xuan, Li [1 ]
Liu, Qifa [1 ]
机构：
[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Dept Hematol, Nanning, Peoples R China
[3] Shenzhen Second Peoples Hosp, Dept Hematol, Shenzhen, Peoples R China
[4] Zhongshan City Peoples Hosp, Dept Hematol, Zhongshan, Peoples R China
[5] Southern Med Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
[6] Guangzhou Med Univ, Affiliated Hosp 2, Dept Hematol, Guangzhou, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
homoharringtonine; venetoclax/azacitidine; acute myeloid leukemia; efficacy; safety;
D O I：
10.1182/blood-2024-206872
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4283 / 4283
页数：1
相关论文
共 50 条
  • [31] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
    Short, Nicholas J.
    Sedarati, Farhad
    Zhao, Dan
    Tsukurov, Olga
    Friedlander, Sharon
    Faller, Douglas V.
    BLOOD, 2020, 136
  • [32] Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia
    Mims, Alice
    Xie, Zhuoer
    Potluri, Ravi
    Rotter, David
    Chevli, Manoj
    Prebet, Thomas
    Gaugler, Lona
    Strocchia, Maria
    Vasconcelos, Alberto
    Sieluk, Jan
    LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 479 - 487
  • [33] High Efficacy of Azacitidine Plus Hag in Acute Myeloid Leukemia: A Multi-Center, Phase 2 Clinical Trial
    Li, Jun
    Han, Qi
    Huang, Yanqing
    Wei, Yanhui
    Zi, Jie
    Zhao, Lidong
    Cai, Zhimei
    Lu, Xuzhang
    Xiao, Rong
    Zhang, Yanmin
    Yang, Xiaotian
    Xu, Hao
    Sun, Naitong
    Zhuang, Wanchuan
    Wu, Zhengdong
    Xia, Yuan
    Xu, Yanli
    He, Bin
    Zhu, Wei
    Min, Fengling
    Chen, Yongchun
    Ding, Banghe
    Shi, Peimin
    Xie, Jing
    Tang, Hua
    Liu, Zefa
    Li, Bingzong
    Sun, Yu
    Qiu, Hongxia
    Duan, Limin
    Song, Chunhua
    Ge, Zheng
    BLOOD, 2022, 140 : 6167 - 6169
  • [34] Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
    Jonas, Brian A.
    Wei, Andrew H.
    Recher, Christian
    DiNardo, Courtney D.
    Jang, Jun-Ho
    Pratz, Keith
    Panayiotidis, Panayiotis
    Montesinos, Pau
    Yeh, Su-Peng
    Ivanov, Vladimir
    Fiedler, Walter
    Yamauchi, Takahiro
    Duan, Yinghui
    Mendes, Wellington
    Potluri, Jalaja
    Tews, Bjorn
    Ofran, Yishai
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (08) : E299 - E303
  • [35] Efficacy and Safety of Decitabine Combined with IA Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
    Kuang, Lifen
    Li, Juan
    BLOOD, 2021, 138
  • [36] VENETOCLAX IN COMBINATION WITH AZACITIDINE IS COST-EFFECTIVE VS. AZA FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A CANADIAN PERSPECTIVE
    Guinan, K.
    Mathurin, K.
    Au, Y.
    Schuh, A. C.
    Bui, C. N.
    Chai, X.
    Lachaine, J.
    VALUE IN HEALTH, 2022, 25 (07) : S344 - S344
  • [37] Venetoclax Combined with Homoharringtonine and Cytarabine (HAV) As Induction Treatment in Elder or Intensive Chemotherapy (IC) Ineligible Patients with Newly Diagnosed Acute Myeloid Leukemia
    Liu, Kaiqi
    Suo, Xiaohui
    Bai, Guanchen
    Yan, Zhangsong
    Li, Yang
    Zhang, Bin
    He, Jinsong
    Wei, Shuning
    Li, Qiuling
    Hu, Bo
    Mi, Yingchang
    BLOOD, 2023, 142
  • [38] Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China
    Yu, Guopan
    Yin, Zhao
    Xu, Dan
    Jiang, Xuejie
    Ye, Jieyu
    Zhang, Yu
    BLOOD, 2022, 140 : 11740 - 11740
  • [39] How to Improve the Efficacy of Venetoclax and Azacitidine(VA)for Newly Diagnosed Acute Myeloid Leukemia?a Prospective, Single-Center, Single-Arm, Phase 2 Trial for New Diagnosed AML
    Li, Xuekai
    Li, Mengyun
    Cui, Wei
    Chen, Xiaoqian
    Yu, Yan
    Chen, Juan
    Zhang, Xin
    Cui, Qingya
    Wu, Depei
    Tang, Xiaowen
    BLOOD, 2024, 144 : 4284 - 4284
  • [40] A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
    Fathi, Amir T.
    Fell, Geoffrey G.
    El-Jawahri, Areej
    Perl, Alexander E.
    Jonas, Brian A.
    Dias, Ajoy L.
    Mims, Alice S.
    Borate, Uma
    Ragon, Brittany Knick
    Grunwald, Michael R.
    Peters, Mary Linton B.
    Graubert, Timothy A.
    Amrein, Philip C.
    Hock, Hanno R.
    Brunner, Andrew M.
    Hobbs, Gabriela S.
    Narayan, Rupa
    Neuberg, Donna S.
    Aldoss, Ibrahim
    BLOOD, 2022, 140 : 3284 - 3286
12345